ArticleClinical and experimental immunology2021
Identification of a unique anti-Ro60 subset with restricted serological and molecular profiles.
Article in Clinical and experimental immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 18 citations in OpenAlex.
- Laboratory pitfalls of antinuclear antibody testing.Clinical rheumatology · 2026Article
- Non-Conventional and Emerging Autoantibodies in Sjögren's Disease.Journal of inflammation research · 2026Review
- Ro60-Roles in RNA Processing, Inflammation, and Rheumatic Autoimmune Diseases.International journal of molecular sciences · 2024Review
- Autoantibody phenotyping of antinuclear antibody-negative systemic lupus erythematosus patients.Archives of rheumatology · 2024Article
- Phases and Natural History of Sjögren's Disease: A New Model for an Old Disease?Arthritis care & research · 2023Review
- Serological intermolecular epitope spreading in a patient with primary Sjögren's syndrome.BMJ case reports · 2023Article
- Antibodies to Both Ro52 and Ro60 for Identifying Sjögren's Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying Therapies.Arthritis care & research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-Ro60 is one of the most common and clinically important serum autoantibodies that has a number of diagnostic and predictive capabilities. Most diagnostic laboratories report this simply as a qualitative positive/negative result. The objective of this study was to examine the clinical and serological relevance of a novel subset of anti-Ro60 in patients who display low levels of anti-Ro60 (anti-Ro60
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.